Fig. 4From: Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in ChinaCost-effectiveness acceptability curve of empagliflozin + SoC versus sitagliptin + SoC and liraglutide + SoC. Empa empagliflozin, Lira liraglutide, QALE quality-adjusted life expectancy, Sita sitagliptin, SoC standard of careBack to article page